High density DNA methylation array is a reliable alternative for PCR-based analysis of the MGMT promoter methylation status in glioblastoma.
暂无分享,去创建一个
David T. W. Jones | Anne K. Braczynski | A. von Deimling | D. Capper | D. Stichel | M. Mittelbronn | P. Harter | J. Schittenhelm
[1] M. Gilbert,et al. MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials , 2018, Clinical Cancer Research.
[2] David T. W. Jones,et al. DNA methylation-based classification of central nervous system tumours , 2018, Nature.
[3] Leiming Wang,et al. Comparative assessment of three methods to analyze MGMT methylation status in a series of 350 gliomas and gangliogliomas. , 2017, Pathology, research and practice.
[4] R. Fimmers,et al. ACTR-58. PHASE III TRIAL OF CCNU/TEMOZOLOMIDE (TMZ) COMBINATION THERAPY VS. STANDARD TMZ THERAPY FOR NEWLY DIAGNOSED MGMT-METHYLATED GLIOBLASTOMA PATIENTS: THE CeTeg/NOA-09 trial , 2017 .
[5] N. Lindeman,et al. The Clinical Implications of Inconsistently Methylated Results from Glioblastoma MGMT Testing by Replicate Methylation-Specific PCR. , 2016, The Journal of molecular diagnostics : JMD.
[6] F. Ducray,et al. Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial , 2016, Oncotarget.
[7] G. Reifenberger,et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.
[8] C. Sommer,et al. MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response , 2016, Clinical Epigenetics.
[9] Mauro Delorenzi,et al. Sensitivity Analysis of the MGMT-STP27 Model and Impact of Genetic and Epigenetic Context to Predict the MGMT Methylation Status in Gliomas and Other Tumors. , 2016, The Journal of molecular diagnostics : JMD.
[10] A. Saâd,et al. MGMT methylation assessment in glioblastoma: MS-MLPA versus human methylation 450K beadchip array and immunohistochemistry , 2016, Clinical and Translational Oncology.
[11] D. Amadori,et al. Defining the cutoff value of MGMT gene promoter methylation and its predictive capacity in glioblastoma , 2016, Journal of Neuro-Oncology.
[12] H. Heinzl,et al. Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questions , 2015, Clinical neuropathology.
[13] Anne K. Braczynski,et al. Confounding Factors in Diagnostics of MGMT Promoter Methylation Status in Glioblastomas in Stereotactic Biopsies , 2014, Stereotactic and Functional Neurosurgery.
[14] M. Sanson,et al. Outcome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patients , 2014, Journal of Neuro-Oncology.
[15] M. Delorenzi,et al. MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status , 2012, Acta Neuropathologica.
[16] G. Reifenberger,et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. , 2012, The Lancet. Oncology.
[17] H. Zentgraf,et al. Characterization of R132H Mutation‐specific IDH1 Antibody Binding in Brain Tumors , 2010, Brain pathology.
[18] Santosh Kesari,et al. Malignant gliomas in adults. , 2008, The New England journal of medicine.
[19] Ivo G Gut,et al. DNA methylation analysis by pyrosequencing , 2007, Nature Protocols.
[20] P. Kleihues,et al. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. , 2005, Journal of neuropathology and experimental neurology.
[21] R. Mirimanoff,et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.
[22] A. Dullea,et al. MGMT testing allows for personalised therapy in the temozolomide era , 2015, Tumor Biology.